LiDCO Group Plc, the UK-based AIM-traded cardiovascular monitoring company is pleased to announce that it has converted US$445,000 of the US$2 million three year secured revolving convertible loan raised on 10th August 2005 from Laurus Master Fund, Ltd. (“Laurus”). As a result 1,166,920 new shares in the Company have been issued at a conversion price of 22.21p (being, in accordance with the terms of the agreement with Laurus, the lower of 24p or 85% of the average closing price for the preceding 10 trading days). The new shares represent 1.16% of the enlarged issued share capital. Admission to trading is expected to take place on 21 November 2005.

LiDCO has the right to convert further amounts of the Laurus loan subject to certain limitations under the agreement with Laurus. In particular, Laurus is restricted from holding 3% or more of the Company’s issued share capital at any one time on any conversion of the loan.

Dr Terry O’Brien, CEO of LiDCO, stated: “I am pleased that LiDCO’s share trading performance has allowed us to achieve a significant conversion of the Laurus loan facility so soon after it was implemented. The conversion allows us additional headroom under the facility, which provides us with significant financial flexibility to underpin our working capital, as we continue to grow sales of LiDCO’s minimally invasive cardiovascular monitoring products.”

Notes to Editors

About Laurus Capital Management LLC

Laurus is a US based financial institution that provides finance to small and micro cap growth companies. Their flexible financing solutions are designed to help build cash reserves and enable management to focus on operations and strategic growth opportunities.

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO’s technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas’ Hospital, London where the Company maintains a research base.

The Company’s manufacturing facility is in Hoxton, London and its current products are: 

• LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;

• LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:

The Company has now achieved registration of its products in 13 markets in Europe, the USA, Brazil and Japan.  It sells direct to the NHS in the UK, and through a worldwide network of specialty critical care distributors.